drugset / Trial / NCT06793449
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.
Timeline
- Start
- 2025-02-05
- Primary completion
- 2026-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-BCMA CAR-T | Cell therapy | 2 cells/kg | Intravenous |
| Subject | anti-BCMA CAR-T | Cell therapy | 4 cells/kg | Intravenous |